Aubex Therapeutics Inc., a pioneering biotechnology firm, announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment (TME).

Aubex’s R&D program shows promise, particularly in cancers where fibrosis drives progression, such as HER2+ and triple-negative (TN) breast cancers, pancreatic cancer, esophageal squamous cell carcinoma (SCC), colon cancer, and non-small cell lung cancer. These solid tumors are notable for their pronounced fibrotic response, which impedes effective immune responses.

Jeffrey A. Glazer expressed his excitement about the company's mission, stating, "Aubex Therapeutics is thrilled to launch with a unique R&D program addressing the TME. This innovative program demonstrates promising early activity in altering the tumor microenvironment, marking a significant milestone in immuno-oncology. We are eager to lead the way in developing therapies that hold the potential to dramatically improve outcomes for cancer patients by reducing fibrosis and boosting a patient’s immune response."

The launch of Aubex Therapeutics marks a pivotal moment in the ongoing effort to develop more effective cancer treatments. With a focus on achieving groundbreaking progress in the therapy of solid tumors, Aubex is dedicated to improving patient outcomes through innovative research.